 <h1>Bleomycin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of bleomycin include:</b> pulmonary toxicity.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to bleomycin: injection powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Injection route (Powder for Solution)</p><p>Pulmonary fibrosis is the most severe toxicity for bleomycin and its most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis. Its occurrence is higher in elderly patients and in those receiving greater than 400 units total dose, but pulmonary toxicity has been observed in young patients and those treated with low doses. A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in lymphoma patients treated with bleomycin.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, bleomycin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking bleomycin:</p><p>
<i>More common</i>
</p><ul>
<li>Fever and chills (occurring within 3 to 6 hours after a dose) </li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Confusion</li>
<li>faintness</li>
<li> wheezing</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Chest pain (sudden severe)</li>
<li>weakness in arms or legs (sudden)</li>
</ul><p>Check with your doctor as soon as possible if any of the following side effects occur while taking bleomycin:</p><p>
<i>More common</i>
</p><ul>
<li>Cough</li>
<li>shortness of breath</li>
<li>sores in mouth and on lips</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of bleomycin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Darkening or thickening of skin</li>
<li>dark stripes on skin</li>
<li>itching of skin</li>
<li> skin rash or colored bumps on fingertips, elbows, or palms</li>
<li> skin redness or tenderness</li>
<li>swelling of fingers</li>
<li>vomiting and loss of appetite</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Changes in fingernails or toenails</li>
<li> weight loss</li>
</ul><p>Bleomycin may cause a temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although it may take several months.</p><p>Side effects that affect your lungs (for example, cough and shortness of breath) may be more likely to occur if you smoke.</p><p>After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, <b>Check with your doctor immediately</b> if you notice the following side effects:</p><ul>
<li>Cough</li>
<li>shortness of breath</li>
</ul><p>
<!-- end injection powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bleomycin: injectable powder for injection</i></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Interstitial pneumonia (10%), pulmonary fibrosis (10%)</p>
<p><b>Common</b> (1% to 10%): Wheezing<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Sclerosis of the skin (41%), pigmentation disorder (41%), alopecia (30%), nail deformation (11%), nail discoloration, skin hypertrophy, flagellate dermatitis</p>
<p><b>Common</b> (1% to 10%): Rash, urticaria, exfoliative dermatitis<sup>[Ref]</sup></p><p>Skin toxicity is a relatively late manifestation, usually developing in the 2nd and 3rd week of treatment, after a cumulative dose of 150 to 200 units.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (15%), vomiting (15%), stomatitis (13%)</p>
<p><b>Common</b> (1% to 10%): Angular cheilitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Diarrhea<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Shock, vein wall hypertrophy, venous stenosis</p>
<p><b>Frequency not reported</b>: Myocardial infarction, hypotension, Raynaud's phenomenon, embolism, thrombosis, peripheral ischemia, cerebral infarction, chest pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever/pyrexia (40%), malaise (16%)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site induration</p>
<p><b>Frequency not reported</b>: Injection site thrombosis (IV), injection site pain<sup>[Ref]</sup></p><h3>Oncologic</h3><p>The most frequent mutations produced in mammalian cells are large multilocus deletions, which probably arise by misrepair of (DNA) double strand breaks.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Tumor pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Hemorrhage</p>
<p><b>Uncommon</b> (0.1% to 1%): Leucopenia</p>
<p><b>Frequency not reported</b>: Pancytopenia, thrombocytopenia, anemia, neutropenia</p>
<p><b>Postmarketing reports</b>:</p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Sepsis</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Scleroderma, chills</p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (29%), weight loss (29%)</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Mental confusion</p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Oliguria, dysuria, pollakiuria, urinary retention, polyuria, feeling of residual urine</p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatocellular injury</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Rigors (40%)</p>
<p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Dizziness</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Wilson KS, Worth A, Richards AG, Ford HS "Low-dose bleomycin lung." Med Pediatr Oncol 10 (1982): 283-8</p><p id="ref_2">2. Zucker PK, Khouri NF, Rosenshein NB "Bleomycin-induced pulmonary nodules: a variant of bleomycin pulmonary toxicity." Gynecol Oncol 28 (1987): 284-91</p><p id="ref_3">3. Maher J, Daly PA "Severe bleomycin lung toxicity: reversal with high dose corticosteroids." Thorax 48 (1993): 92-4</p><p id="ref_4">4. Chisholm RA, Dixon AK, Williams MV, Oliver RTD "Bleomycin lung: the effect of different chemotherapeutic regimens." Cancer Chemother Pharmacol 30 (1992): 158-60</p><p id="ref_5">5. "Product Information. Blenoxane (bleomycin)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_6">6. McLeod BF, Lawrence HJ, Smith DW, Vogt PJ, Gandara DR "Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency." Cancer 60 (1987): 2617-20</p><p id="ref_7">7. Hartmann LC, Frytak S, Richardson RL, Coles DT, Cupps RE "Life-threatening bleomycin pulmonary toxicity with ultimate reversibility." Chest 98 (1990): 497-9</p><p id="ref_8">8. Doll DC "Fatal pneumothorax associated with bleomycin-induced pulmonary fibrosis." Cancer Chemother Pharmacol 17 (1986): 294-5</p><p id="ref_9">9. Bechard DE, Fairman RP, DeBlois GG, Via CT "Fatal pulmonary fibrosis from low-dose bleomycin therapy." South Med J 80 (1987): 646-9</p><p id="ref_10">10. Khansur T, Little D, Tavassoli M "Fulminant and fatal angioedema caused by bleomycin treatment." Arch Intern Med 144 (1984): 2267</p><p id="ref_11">11. Leeser JE, Carr D "Fatal pneumothorax following bleomycin and other cytotoxic drugs." Cancer Treat Rep 69 (1985): 344-5</p><p id="ref_12">12. Sleijfer S "Bleomycin-induced pneumonitis." Chest 120 (2001): 617+</p><p id="ref_13">13. Bennett WM, Pastore L, Houghton DC "Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure." Cancer Treat Rep 64 (1980): 921-4</p><p id="ref_14">14. Jones AW "Bleomycin lung damage: the pathology and nature of the lesion." Br J Dis Chest 72 (1978): 321-6</p><p id="ref_15">15. Brown WG, Hasan FM, Barbee RA "Reversibility of severe bleomycin-induced pneumonitis." JAMA 239 (1978): 2012-4</p><p id="ref_16">16. Dalgleish AG, Woods RL, Levi JA "Bleomycin pulmonary toxicity: its relationship to renal dysfunction." Med Pediatr Oncol 12 (1984): 313-7</p><p id="ref_17">17. Wolkowicz J, Sturgeon J, Rawji M, Chan CK "Bleomycin-induced pulmonary function abnormalities." Chest 101 (1992): 97-101</p><p id="ref_18">18. Arseculeratne G,  Berroeta L,  Meiklejohn D, et al. "Bleomycin-induced "flagellate dermatitis"." Arch Dermatol 143 (2007): 1461-2</p><p id="ref_19">19. Kerr LD, Spiera H "Scleroderma in association with the use of bleomycin: a report of 3 cases." J Rheumatol 19 (1992): 294-6</p><p id="ref_20">20. "Multum Information Services, Inc. Expert Review Panel"  </p></div>
<div class="more-resources" id="moreResources">
<h2>More about bleomycin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: antibiotics/antineoplastics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Bleomycin Injection &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Blenoxane</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hodgkin's Lymphoma</li>
<li>Testicular Cancer</li>
<li>Malignant Pleural Effusion</li>
<li>Non-Hodgkin's Lymphoma</li>
<li>Squamous Cell Carcinoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bleomycin: injectable powder for injection</i></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Interstitial pneumonia (10%), pulmonary fibrosis (10%)</p><p><b>Common</b> (1% to 10%): Wheezing<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Sclerosis of the skin (41%), pigmentation disorder (41%), alopecia (30%), nail deformation (11%), nail discoloration, skin hypertrophy, flagellate dermatitis</p><p><b>Common</b> (1% to 10%): Rash, urticaria, exfoliative dermatitis<sup>[Ref]</sup></p><p>Skin toxicity is a relatively late manifestation, usually developing in the 2nd and 3rd week of treatment, after a cumulative dose of 150 to 200 units.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (15%), vomiting (15%), stomatitis (13%)</p><p><b>Common</b> (1% to 10%): Angular cheilitis</p><p><b>Uncommon</b> (0.1% to 1%): Diarrhea<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Shock, vein wall hypertrophy, venous stenosis</p><p><b>Frequency not reported</b>: Myocardial infarction, hypotension, Raynaud's phenomenon, embolism, thrombosis, peripheral ischemia, cerebral infarction, chest pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever/pyrexia (40%), malaise (16%)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Injection site induration</p><p><b>Frequency not reported</b>: Injection site thrombosis (IV), injection site pain<sup>[Ref]</sup></p><h3>Oncologic</h3><p>The most frequent mutations produced in mammalian cells are large multilocus deletions, which probably arise by misrepair of (DNA) double strand breaks.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Tumor pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Hemorrhage</p><p><b>Uncommon</b> (0.1% to 1%): Leucopenia</p><p><b>Frequency not reported</b>: Pancytopenia, thrombocytopenia, anemia, neutropenia</p><p><b>Postmarketing reports</b>:</p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Sepsis</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Scleroderma, chills</p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (29%), weight loss (29%)</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Mental confusion</p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Oliguria, dysuria, pollakiuria, urinary retention, polyuria, feeling of residual urine</p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatocellular injury</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Rigors (40%)</p><p><b>Common</b> (1% to 10%): Headache</p><p><b>Uncommon</b> (0.1% to 1%): Dizziness</p><p id="ref_1">1. Wilson KS, Worth A, Richards AG, Ford HS "Low-dose bleomycin lung." Med Pediatr Oncol 10 (1982): 283-8</p><p id="ref_2">2. Zucker PK, Khouri NF, Rosenshein NB "Bleomycin-induced pulmonary nodules: a variant of bleomycin pulmonary toxicity." Gynecol Oncol 28 (1987): 284-91</p><p id="ref_3">3. Maher J, Daly PA "Severe bleomycin lung toxicity: reversal with high dose corticosteroids." Thorax 48 (1993): 92-4</p><p id="ref_4">4. Chisholm RA, Dixon AK, Williams MV, Oliver RTD "Bleomycin lung: the effect of different chemotherapeutic regimens." Cancer Chemother Pharmacol 30 (1992): 158-60</p><p id="ref_5">5. "Product Information. Blenoxane (bleomycin)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_6">6. McLeod BF, Lawrence HJ, Smith DW, Vogt PJ, Gandara DR "Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency." Cancer 60 (1987): 2617-20</p><p id="ref_7">7. Hartmann LC, Frytak S, Richardson RL, Coles DT, Cupps RE "Life-threatening bleomycin pulmonary toxicity with ultimate reversibility." Chest 98 (1990): 497-9</p><p id="ref_8">8. Doll DC "Fatal pneumothorax associated with bleomycin-induced pulmonary fibrosis." Cancer Chemother Pharmacol 17 (1986): 294-5</p><p id="ref_9">9. Bechard DE, Fairman RP, DeBlois GG, Via CT "Fatal pulmonary fibrosis from low-dose bleomycin therapy." South Med J 80 (1987): 646-9</p><p id="ref_10">10. Khansur T, Little D, Tavassoli M "Fulminant and fatal angioedema caused by bleomycin treatment." Arch Intern Med 144 (1984): 2267</p><p id="ref_11">11. Leeser JE, Carr D "Fatal pneumothorax following bleomycin and other cytotoxic drugs." Cancer Treat Rep 69 (1985): 344-5</p><p id="ref_12">12. Sleijfer S "Bleomycin-induced pneumonitis." Chest 120 (2001): 617+</p><p id="ref_13">13. Bennett WM, Pastore L, Houghton DC "Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure." Cancer Treat Rep 64 (1980): 921-4</p><p id="ref_14">14. Jones AW "Bleomycin lung damage: the pathology and nature of the lesion." Br J Dis Chest 72 (1978): 321-6</p><p id="ref_15">15. Brown WG, Hasan FM, Barbee RA "Reversibility of severe bleomycin-induced pneumonitis." JAMA 239 (1978): 2012-4</p><p id="ref_16">16. Dalgleish AG, Woods RL, Levi JA "Bleomycin pulmonary toxicity: its relationship to renal dysfunction." Med Pediatr Oncol 12 (1984): 313-7</p><p id="ref_17">17. Wolkowicz J, Sturgeon J, Rawji M, Chan CK "Bleomycin-induced pulmonary function abnormalities." Chest 101 (1992): 97-101</p><p id="ref_18">18. Arseculeratne G,  Berroeta L,  Meiklejohn D, et al. "Bleomycin-induced "flagellate dermatitis"." Arch Dermatol 143 (2007): 1461-2</p><p id="ref_19">19. Kerr LD, Spiera H "Scleroderma in association with the use of bleomycin: a report of 3 cases." J Rheumatol 19 (1992): 294-6</p><p id="ref_20">20. "Multum Information Services, Inc. Expert Review Panel"  </p><h2>More about bleomycin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: antibiotics/antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Bleomycin Injection &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hodgkin's Lymphoma</li>
<li>Testicular Cancer</li>
<li>Malignant Pleural Effusion</li>
<li>Non-Hodgkin's Lymphoma</li>
<li>Squamous Cell Carcinoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>